Pharmaceutical

AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine  

The company revealed the data at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference 2024.

Mar 9, 2024 - 18:00
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine  
The company revealed the data at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference 2024.
Read the original article

Tags:

Previous Article

BeiGene secures accelerated FDA approval for follicular lymphoma treatment

Next Article

Amylyx considers scrapping ALS drug following Phase III flop

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulatory panel weighing against approval of Amylyx’s ALS therapy, company says

STAT+: European regulatory panel weighing against appro...

May 31, 2023

STAT+: House Republicans call CDC director to testify

STAT+: House Republicans call CDC director to testify

Nov 21, 2023

Trametinib dimethyl sulfoxide by Novartis for Relapsed ...

Oct 25, 2023